BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement

Core Viewpoint - BioPorto A/S has initiated a pre-subscribed private placement of up to 40,438,426 new shares to support its financing strategy aimed at achieving positive cash flow by the second half of 2027 [3][4][5]. Financing Strategy - The company identified a funding need of DKK 60–70 million to complete a U.S. clinical study and strengthen its commercial platform [4]. - A variety of financing alternatives were evaluated, including equity issuance and strategic financing solutions, to support long-term growth [4]. Private Placement Details - The private placement is fully pre-subscribed, with indications for the entire amount, expected to raise approximately DKK 43 million [5][9]. - The subscription price is set at DKK 1.072, matching the closing price of BioPorto shares on Nasdaq Copenhagen on the announcement date [9]. Share Offering Terms - The offering includes up to 40,438,426 new shares, representing 8.89% of the company's registered share capital prior to the increase [8]. - The new shares will carry the same rights as existing shares and will be registered through VP Securities A/S [10]. Timeline and Trading - The subscription period has commenced and will close at short notice, with results to be announced shortly thereafter [12]. - New shares are expected to be listed on Nasdaq Copenhagen by November 26, 2025, subject to the offering not being withdrawn [13]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management [15][16]. - The company's flagship products are based on the NGAL biomarker, aiding in the risk assessment and management of Acute Kidney Injury (AKI) [16].